Cytocom Statistics

Share Statistics

Cytocom has 71.42M shares outstanding. The number of shares has increased by 0% in one year.

Shares Outstanding	71.42M
Shares Change (YoY)	0%
Shares Change (QoQ)	0%
Owned by Institutions (%)	n/a
Shares Floating	47.55M
Failed to Deliver (FTD) Shares	n/a
FTD / Avg. Volume	n/a

Short Selling Information

The latest short interest is 9.99K, so 0% of the outstanding shares have been sold short.

Short Interest	9.99K
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	1

Valuation Ratios

The PE ratio is -17.83 and the forward PE ratio is null. Cytocom's PEG ratio is 1.03.

PE Ratio	-17.83
Forward PE	n/a
PS Ratio	162.65
Forward PS	n/a
PB Ratio	21.24
P/FCF Ratio	-18.02
PEG Ratio	1.03

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Cytocom.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 7.6, with a Debt / Equity ratio of 0.

Current Ratio	7.6
Quick Ratio	7.6
Debt / Equity	0
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$14.61K
Profits Per Employee	$-133.25K
Employee Count	18
Asset Turnover	0.11
Inventory Turnover	n/a

Taxes

Income Tax	148.68K
Effective Tax Rate	-6.1%

Stock Price Statistics

The stock price has increased by 0% in the last 52 weeks. The beta is 0.68, so Cytocom's price volatility has been higher than the market average.

Beta	0.68
52-Week Price Change	n/a
50-Day Moving Average	n/a
200-Day Moving Average	n/a
Relative Strength Index (RSI)	n/a
Average Volume (20 Days)	156,953

Income Statement

In the last 12 months, Cytocom had revenue of 262.94K and earned -2.4M in profits. Earnings per share was -0.19.

Revenue	262.94K
Gross Profit	262.94K
Operating Income	-2.59M
Net Income	-2.4M
EBITDA	-2.39M
EBIT	n/a
Earnings Per Share (EPS)	-0.19

Full Income Statement

Balance Sheet

The company has 1.95M in cash and 0 in debt, giving a net cash position of 1.95M.

Cash & Cash Equivalents	1.95M
Total Debt	n/a
Net Cash	n/a
Retained Earnings	-169.1M
Total Assets	13.83M
Working Capital	13.52M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -2.37M and capital expenditures 0, giving a free cash flow of -2.37M.

Operating Cash Flow	-2.37M
Capital Expenditures	n/a
Free Cash Flow	-2.37M
FCF Per Share	-0.19

Full Cash Flow Statement

Margins

Gross margin is 100%, with operating and profit margins of -983.7% and -912.16%.

Gross Margin	100%
Operating Margin	-983.7%
Pretax Margin	-927.15%
Profit Margin	-912.16%
EBITDA Margin	-907.81%
EBIT Margin	-983.7%
FCF Margin	-902.47%

Dividends & Yields

CBLI does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

Currently there are no analyst rating for CBLI.

Price Target	n/a
Price Target Difference	n/a
Analyst Consensus	n/a
Analyst Count	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on Jan 28, 2015. It was a backward split with a ratio of 1:20.

Last Split Date	Jan 28, 2015
Split Type	backward
Split Ratio	1:20

Scores

Altman Z-Score	435.14
Piotroski F-Score	1

Cytocom Inc. (CBLI)